What is BioMarin?
BioMarin Pharmaceutical Inc. is a biotechnology company dedicated to developing and commercializing innovative therapies for individuals affected by serious and life-threatening rare diseases and medical conditions. The company's portfolio includes enzyme replacement therapies and other treatments for conditions such as mucopolysaccharidosis (MPS) IV type A, MPS VI, phenylketonuria (PKU), and certain forms of Batten disease. BioMarin also has a pipeline including treatments for achondroplasia and hemophilia A, positioning it as a key player in addressing unmet medical needs within the rare disease space.
How much funding has BioMarin raised?
BioMarin has raised a total of $58.5M across 1 funding round:
Stock Offering
$58.5M
Stock Issuance/Offering (1999): $58.5M, investors not publicly disclosed
What's next for BioMarin?
With a substantial enterprise-level funding injection, BioMarin is poised for accelerated growth and the expansion of its therapeutic pipeline. This strategic investment will likely fuel further research and development, clinical trials, and the commercialization of its promising treatments for rare genetic disorders. The company's focus on complex biological challenges suggests a continued trajectory of innovation and market leadership in the specialized biopharmaceutical landscape.
See full BioMarin company page
